Targeting TIGIT may prevent CAR-T-related relapses and thus promote long-term progression-free survival in mantle cell lymphoma (MCL) patients, according to another study that found that over-expression of TIGIT played a critical role in T-cell suppression associated with CAR-T relapse in mantle cell lymphoma patients [44]. Here, TIGIT is linked to mantle cell lymphoma.